Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer.
Zanidatamab is a bispecific antibody drug developed for treating certain types of cancer, particularly HER2-positive cancers
It is an IgG-like bispecific HER2-directed antibody directed against two non-overlapping domains of HER2.
Binds to two distinct sites on the HER2 receptor simultaneously
This dual binding is designed to provide more potent anti-tumor activity compared to single-target HER2 therapies
Blocks HER2 signaling pathways that drive cancer cell growth and survival
The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue.
A first-in-class medication.
Zanidatamabis indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.
Contains a boxed warning for embryo-fetal toxicity.
The most common adverse reactions include diarrhea, infusion-related reactions, abdominal pain, and fatigue.